Humana (NYSE:HUM) had its price target upped by SunTrust Banks to $335.00 in a research report report published on Thursday, The Fly reports. They currently have a hold rating on the insurance provider’s stock. SunTrust Banks also issued estimates for Humana’s Q4 2019 earnings at $2.22 EPS, FY2019 earnings at $17.78 EPS, Q1 2020 earnings at $4.80 EPS, Q2 2020 earnings at $5.94 EPS, Q3 2020 earnings at $5.04 EPS, Q4 2020 earnings at $2.86 EPS and FY2020 earnings at $18.64 EPS. The analysts noted that the move was a valuation call.
Several other research firms have also issued reports on HUM. Canaccord Genuity reiterated a buy rating on shares of Humana in a research note on Monday, October 21st. ValuEngine upgraded Humana from a sell rating to a hold rating in a research note on Wednesday, October 2nd. Deutsche Bank initiated coverage on Humana in a research note on Thursday, September 12th. They set a hold rating and a $300.00 price target on the stock. Piper Jaffray Companies boosted their price target on Humana from $315.00 to $341.00 and gave the stock an overweight rating in a research note on Thursday, August 1st. Finally, UBS Group boosted their price target on Humana from $266.00 to $317.00 and gave the stock a neutral rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $322.63.
HUM traded up $2.44 on Thursday, hitting $317.58. The company had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. The stock has a fifty day moving average price of $277.48 and a 200-day moving average price of $270.93. Humana has a 12-month low of $225.65 and a 12-month high of $342.03. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. The stock has a market capitalization of $39.82 billion, a price-to-earnings ratio of 21.83, a P/E/G ratio of 1.27 and a beta of 0.85.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.55 per share. The ex-dividend date is Monday, December 30th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.69%. Humana’s payout ratio is 15.12%.
In other news, insider Brian P. Leclaire sold 7,239 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the sale, the insider now owns 12,994 shares in the company, valued at $3,764,361.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.54% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Whittier Trust Co. purchased a new stake in Humana in the second quarter valued at approximately $27,000. Next Capital Management LLC purchased a new stake in Humana in the second quarter valued at approximately $27,000. Endurance Wealth Management Inc. boosted its position in Humana by 354.5% in the third quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after buying an additional 78 shares during the last quarter. Quest Capital Management Inc. ADV purchased a new stake in Humana in the third quarter valued at approximately $30,000. Finally, Advantage Investment Management LLC boosted its position in Humana by 287.1% in the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock valued at $32,000 after buying an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 92.93% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: What is insider trading?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.